second
part
narr
review
nurs
homeassoci
pneumonia
nhap
deal
etiolog
treatment
nurs
home
etiolog
nhap
consid
similar
communityacquir
pneumonia
cap
belief
reflect
cap
guidelin
design
healthcareassoci
pneumonia
hcap
introduc
nurs
home
resid
includ
hcap
categori
patient
hcap
group
thought
high
risk
pneumonia
multidrug
resist
organ
requir
empir
broadspectrum
antibiot
therapi
much
like
peopl
hospitalacquir
infect
subsequ
studi
etiolog
nhap
use
sophist
diagnost
test
found
limit
evid
resist
organ
methicillinresist
staphylococcu
aureu
resist
gramneg
organ
atyp
organ
term
manag
nhap
nurs
home
sever
consider
discuss
hospit
decis
initi
oral
parenter
therapi
time
switch
oral
regimen
parenter
therapi
initi
prescrib
durat
therapi
emphasi
shorter
cours
followup
therapi
includ
use
antibiot
time
protocol
oral
parenter
antibiot
regimen
recommend
treatment
nhap
report
base
limit
inform
random
control
trial
defin
optimum
regimen
conclus
resid
pneumonia
treat
success
nurs
home
howev
urgent
need
specif
nhap
diagnosi
treatment
guidelin
give
provid
guidanc
manag
infect
nurs
home
second
part
narr
review
nurs
homeassoci
pneumonia
nhap
deal
etiolog
treatment
focu
manag
nurs
home
episod
nhap
treat
set
past
decad
evolut
view
etiolog
nhap
one
similar
communityacquir
pneumonia
cap
one
resist
organ
predomin
term
health
careassoci
pneumonia
hcap
howev
almost
studi
etiolog
nhap
hospit
resid
remain
determin
find
applic
manag
nurs
home
despit
remark
advanc
noncultur
method
detect
organ
clinic
specimen
continu
almost
total
relianc
culturebas
method
identifi
etiolog
agent
suspect
pneumonia
report
provid
clinician
inform
etiolog
nhap
recommend
empir
antibiot
therapi
nurs
home
review
nhap
includ
evalu
studi
publish
provid
inform
etiolog
almost
studi
util
sputum
cultur
identifi
etiolog
howev
result
sputum
cultur
differ
substanti
depend
whether
strict
criteria
polymorphonuclear
leukocyt
epitheli
cell
per
power
field
undilut
sputum
sampl
use
exclud
oropharyng
contamin
sampl
studi
evalu
sputum
sampl
oropharyng
contamin
identifi
gramneg
bacilli
sputum
cultur
wherea
studi
use
strict
criteria
cultur
contain
gramneg
bacilli
studi
util
strict
criteria
streptococcu
pneumonia
isol
sputum
cultur
nontyp
hemophilu
influenza
staphylococcu
aureu
atyp
organ
rare
studi
evalu
virus
role
atyp
organ
mycoplasma
chlamydia
virus
could
determin
due
lack
inform
pathogen
studi
avail
thu
pattern
sputum
isol
resid
pneumonia
resembl
found
hospit
patient
cap
result
review
inform
part
recommend
treatment
nhap
nurs
home
cap
treatment
guidelin
american
thorac
societi
at
collabor
infecti
diseas
societi
america
idsa
publish
updat
treatment
hospitalacquir
pneumonia
includ
guidelin
new
categori
refer
healthcareassoci
pneumonia
hcap
basi
hcap
categori
find
resist
organ
methicillinresist
aureu
mrsa
pseudomona
aeruginosa
identifi
often
patient
commun
infect
pattern
isol
consist
isol
hospitalacquir
pneumonia
cap
hcap
categori
consist
heterogen
group
communitydwel
patient
admit
hospit
pneumonia
tabl
patient
common
risk
factor
frequent
recent
contact
healthcar
system
andor
recent
antibiot
therapi
inclus
nurs
home
resid
hcap
categori
base
studi
resid
sever
pneumonia
admit
intens
care
unit
mechan
ventil
invas
method
identifi
etiolog
pneumonia
util
resid
presum
sever
bacteri
pneumonia
high
rate
isol
gramneg
aerob
bacilli
mrsa
patient
hcap
criteria
guidelin
recommend
empir
broadspectrum
antibiot
therapi
consist
antibiot
antipseudomon
agent
mrsa
would
also
effect
potenti
multidrugresist
gramneg
bacilli
k
pneumonia
acinetobact
speci
rational
recommend
regimen
make
sure
patient
receiv
appropri
therapi
initi
identifi
import
predictor
morbid
mortal
follow
public
atsidsa
guidelin
controversi
develop
regard
valid
concept
patient
pneumonia
admit
hospit
meet
hcap
criteria
high
probabl
infect
resist
organ
requir
empir
broadspectrum
antibiot
therapi
recent
public
review
controversi
detail
major
concern
approach
would
expos
patient
unnecessarili
multipl
antibiot
promot
develop
resist
well
advers
effect
c
difficil
infect
review
found
evid
patient
group
includ
hcap
categori
accur
identifi
presenc
resist
organ
hospit
mortal
increas
patient
categori
adjust
age
comorbid
diseas
addit
major
studi
compar
guidelineconcord
discord
treatment
hcap
demonstr
advantag
broadspectrum
antibiot
therapi
term
hospit
mortal
result
find
approach
shift
hcap
categor
focus
particular
clinic
group
identifi
specif
risk
factor
presenc
resist
organ
appli
gener
sever
algorithm
incorpor
risk
factor
resist
organ
develop
found
perform
better
hcap
criteria
identifi
organ
mani
model
includ
resid
nurs
home
risk
factor
resist
organ
given
pushback
regard
hcap
categori
updat
atsidsa
guidelin
publish
includ
group
indic
would
part
updat
cap
guidelin
sinc
sever
studi
provid
inform
regard
etiolog
nhap
tabl
none
done
unit
state
canada
studi
list
tabl
done
hospit
resid
use
multipl
diagnost
techniqu
includ
polymeras
chain
reaction
identifi
bacteria
virus
size
studi
popul
small
except
studi
proport
case
identifi
etiolog
vari
consist
find
pneumonia
one
common
identifi
caus
nhap
studi
aureu
enterobacteriacea
p
aeruginosa
infrequ
identifi
caus
agent
atyp
organ
c
pneumonia
pneumonia
etiolog
nhap
rare
studi
common
japanes
studi
done
group
investig
method
detect
virus
use
studi
detect
virus
influenza
viru
respiratori
syncyti
viru
common
virus
identifi
one
studi
provid
inform
etiolog
nhap
includ
tabl
specif
organ
identifi
detail
prospect
studi
nurs
resid
admit
hospit
hong
kong
pneumonia
use
methodolog
similar
previou
studi
identifi
etiolog
nhap
episod
bacteria
alon
isol
episod
virus
alon
episod
gramposit
organ
identifi
bacteri
episod
gramneg
organ
episod
consid
multidrug
resist
organ
base
result
studi
appear
one
concern
pneumonia
import
etiolog
agent
nhap
aureu
gramneg
organ
includ
p
aeruginosa
etiolog
nhap
low
overal
role
atyp
organ
caus
nhap
difficult
determin
distinct
differ
rate
identif
pathogen
among
studi
note
final
virus
primarili
influenza
parainfluenza
respiratori
syncyti
viru
identifi
resid
hospit
pneumonia
howev
studi
viru
identifi
conjunct
bacteria
multipl
issu
consid
regard
manag
pneumonia
nurs
home
discuss
section
manag
resid
nurs
home
transfer
hospit
import
initi
decis
treatment
nhap
potenti
advers
effect
hospit
resid
includ
drug
reaction
delirium
decreas
function
statu
pressur
ulcer
increas
mortal
cost
advers
effect
hospit
increas
demand
nurs
home
reduc
hospit
result
studi
defin
potenti
avoid
hospit
nurs
home
resid
pneumonia
one
common
diagnos
associ
maruyama
et
al
pulverino
et
al
et
al
ewig
et
al
putot
et
al
potenti
avoid
hospit
nurs
home
resid
multipl
factor
identifi
result
hospit
resid
suspect
nhap
elev
respiratori
rate
afterhour
evalu
forprofit
facil
ownership
sever
ill
radiograph
pneumonia
oxygen
satur
facil
resourc
nonclin
factor
also
influenc
hospit
decis
need
consid
includ
document
advanc
direct
residentfamili
prefer
physician
prefer
random
control
trial
clinic
pathway
reduc
hospit
resid
pneumonia
lower
respiratori
tract
infect
cluster
random
control
trial
nurs
home
hamilton
ontario
canada
random
clinic
pathway
usual
care
studi
demonstr
clinic
pathway
design
assist
provid
decis
regard
locat
treatment
nhap
significantli
reduc
hospit
intervent
facil
increas
mortal
compar
control
facil
although
clinic
pathway
valid
provid
reason
basi
evalu
resid
suspect
pneumonia
regard
hospit
decis
howev
need
emphas
clinic
pathway
take
place
physicianprovid
judgment
decis
hospit
resid
chang
statu
complex
may
difficult
determin
transfer
avoid
base
inform
avail
prior
transfer
occur
initi
treatment
nurs
home
oral
parenter
rout
determin
made
treat
nhap
nurs
home
next
decis
rout
administr
oral
parenter
use
initi
studi
provid
method
make
decis
initi
rout
treatment
nhap
howev
common
sens
approach
issu
consid
first
swallow
problem
resid
alert
appropri
start
oral
rout
document
effect
treatment
nhap
resid
evid
dysphagia
hour
concern
start
oral
therapi
parenter
intramuscular
therapi
use
first
day
reassess
switch
oral
regimen
see
next
section
retrospect
studi
nhap
nurs
home
done
develop
treatment
guidelin
base
commun
practic
episod
nhap
treat
nurs
home
episod
treat
parenter
initi
intramuscular
ceftriaxon
cefotaxim
median
durat
parenter
treatment
day
percentil
day
differ
rate
hospit
transfer
mortal
treat
parenter
vs
oral
nurs
home
studi
treatment
patient
hospit
cap
investig
develop
criteria
determin
clinic
stabil
achiev
parenter
therapi
assist
decid
switch
oral
regimen
appropri
improv
signssymptom
afebril
hour
acut
cardiac
signific
event
first
day
treatment
abl
take
oral
medic
criteria
met
patient
consid
clinic
stabl
readi
switch
oral
regimen
use
criteria
day
parenter
therapi
nurs
home
resid
achiev
clinic
stabil
switch
oral
regimen
criteria
stabil
readili
avail
nurs
home
staff
resid
monitor
first
day
treatment
includ
antibiot
timeout
protocol
discuss
later
section
assist
provid
make
switch
decis
past
year
clinic
trial
document
durat
antibiot
treatment
common
bacteri
infect
reduc
compar
tradit
longer
regimen
reduct
efficaci
explan
antibiot
regimen
evolv
time
term
durat
trace
back
penicillin
first
becam
avail
treatment
pneumococc
pneumonia
time
appropri
dose
durat
penicillin
effect
treatment
unknown
result
small
dose
penicillin
util
day
excel
result
howev
small
number
relaps
actual
reinfect
longer
cours
treatment
day
recommend
result
earli
studi
penicillin
treatment
pneumococc
pneumonia
inform
decis
regard
treatment
levofloxacin
mg
oral
daili
moxifloxacin
mg
oral
daili
time
switch
oral
regimen
determin
monitor
clinic
stabil
total
durat
therapi
exceed
day
clinic
stabil
achiev
durat
cap
decad
howev
concern
increas
resist
overus
antibiot
well
advers
effect
antibiot
primarili
c
difficil
infect
studi
treatment
cap
well
common
bacteri
infect
document
shorter
durat
regimen
equal
efficaci
longer
regimen
howev
studi
short
durat
treatment
pneumonia
includ
nurs
home
resid
despit
lack
studi
regard
shortcours
day
treatment
nhap
may
possibl
shorten
therapi
infect
resid
could
part
facil
antibiot
stewardship
program
defin
time
point
antibiot
timeout
exampl
treatment
initi
resid
evalu
respons
treatment
respons
meet
clinic
stabil
criteria
previous
discuss
consider
given
limit
durat
therapi
day
nhap
care
monitor
throughout
remaind
treatment
specif
nhap
treatment
guidelin
publish
howev
recommend
treatment
nhap
nurs
home
set
cap
guidelin
idsa
cap
guidelin
state
older
patient
fluoroquinolon
may
prefer
canadian
infecti
diseas
societi
cap
guidelin
first
specif
provid
recommend
treatment
nhap
nurs
home
fluoroquinolon
amoxicillinclavulan
plu
macrolid
at
cap
guidelin
recommend
oral
betalactam
ceftriaxon
plu
macrolid
doxycyclin
fluoroquinolon
alon
treatment
pneumonia
nurs
home
revis
idsa
cap
guidelin
publish
made
recommend
canadian
guidelin
treatment
nhap
nurs
home
sinc
idsa
cap
guidelin
revis
twice
neither
guidelin
made
recommend
treatment
nhap
nurs
home
guidelin
recommend
nurs
home
resid
admit
hospit
pneumonia
treat
accord
atsidsa
guidelin
hcap
made
recommend
treatment
nurs
home
howev
atsidsa
cap
guidelin
recommend
abandon
hcap
classif
assess
patient
risk
factor
determin
need
mrsa
pseudomona
coverag
made
recommend
treatment
nhap
nurs
home
nurs
home
sever
risk
factor
consid
put
resid
risk
pneumonia
due
resist
organ
tabl
import
factor
nurs
home
resid
prior
cultur
posit
resist
organ
especi
respiratori
tract
recent
antibiot
therapi
tabl
provid
recommend
treatment
nhap
nurs
home
risk
factor
resist
organ
tabl
provid
recommend
decis
start
parenter
regimen
follow
switch
oral
regimen
tabl
provid
recommend
decid
treat
oral
agent
sever
point
emphas
recommend
first
concern
use
macrolid
alon
increas
resist
pneumococci
littl
evid
support
clinic
relev
resist
nevertheless
author
latest
cap
guidelin
make
strong
recommend
routin
use
monotherapi
macrolid
outpati
treatment
cap
second
oral
fluoroquinolon
levofloxacin
moxifloxacin
longer
consid
firstlin
agent
treatment
nhap
multipl
potenti
advers
effect
third
necessari
cover
atyp
organ
mycoplasma
chlamydia
although
doxycyclin
fluoroquinolon
provid
coverag
presenc
risk
factor
resist
organ
tabl
decis
treat
nurs
home
depend
risk
factor
present
well
sever
pneumonia
sinc
studi
guid
manag
nhap
situat
follow
comment
repres
author
best
guess
recent
antibiot
therapi
evid
vital
sign
instabl
one
prescrib
antibiot
differ
class
oral
parenter
risk
factor
recent
hospit
antibiot
treatment
clinic
stabil
one
might
opt
treat
oral
parenter
recommend
tabl
histori
colonizationinfect
especi
respiratori
tract
resist
organ
mrsa
pseudomona
aeruginosa
organ
difficult
treat
nurs
home
requir
parenter
therapi
would
appropri
transfer
resid
hospit
manag
import
keep
mind
entiti
aspir
pneumonia
discuss
treatment
nhap
evolv
inform
regard
bacteri
etiolog
infect
aspir
pneumonia
defin
acut
lung
infect
develop
largevolum
aspir
oropharyng
upper
gastrointestin
content
high
enough
ph
avoid
chemic
pneumon
nurs
home
resid
increas
risk
aspir
pneumonia
due
high
rate
dysphagia
popul
relat
dementia
parkinson
diseas
stroke
predispos
larg
volum
aspir
studi
indic
anaerob
common
etiolog
agent
aspir
pneumonia
empir
therapi
prescrib
cover
organ
howev
recent
evalu
aspir
pneumonia
found
anaerob
much
less
like
identifi
infect
studi
nurs
resid
hospit
aspir
pneumonia
intub
mechan
ventil
invas
cultur
method
demonstr
aureu
gramneg
bacilli
commonli
isol
anaerob
latter
find
suggest
regimen
specif
target
anaerob
requir
aspir
pneumonia
diagnosi
nurs
resid
howev
oral
regimen
describ
tabl
treatment
nhap
coverag
anaerob
topic
infrequ
discuss
import
document
provid
thought
process
result
diagnosi
pneumonia
nurs
home
resid
document
includ
histori
sign
symptom
suspect
diagnosi
addit
provid
state
diagnost
studi
order
plan
treatment
pend
workup
result
problem
provid
often
nurs
home
resid
chang
statu
must
reli
nurs
staff
assess
resid
provid
inform
base
decis
nurs
staff
vari
abil
carri
necessari
evalu
bedsid
collect
appropri
inform
call
provid
deal
variabl
templat
develop
assist
nurs
home
staff
evalu
resid
chang
statu
prompt
collect
appropri
inform
call
provid
although
pushback
provid
regard
use
electron
medic
record
emr
emr
use
document
especi
provid
site
cover
provid
thought
process
document
emr
resid
usual
provid
cover
provid
absenc
facetofac
evalu
document
use
followup
discuss
next
section
resid
infect
treat
nurs
home
provid
need
mind
infect
treat
nurs
home
followup
treatment
verifi
respons
check
laboratori
test
order
determin
chang
treatment
requir
decid
durat
therapi
import
followup
nurs
home
antibiot
stewardship
program
consid
incorpor
timeout
protocol
followup
procedur
timeout
protocol
consist
evalu
resid
staff
provid
day
treatment
assess
respons
treatment
determin
regimen
chang
continu
addit
time
determin
durat
treatment
made
exampl
clinic
stabil
achiev
discuss
previou
section
consider
given
complet
treatment
day
timeout
decis
document
medic
record
resid
respond
therapi
necessari
repeat
laboratori
test
chest
radiogram
studi
etiolog
nhap
nurs
home
set
mainli
difficult
obtain
reliabl
respiratori
specimen
cultur
popul
yield
blood
cultur
low
recommend
routin
futur
research
may
abl
util
molecular
test
defin
etiolog
nhap
practic
approach
real
world
set
unclear
given
cost
test
need
test
done
offsit
laboratori
given
rariti
identifi
etiolog
nhap
nurs
home
set
treatment
almost
alway
empir
howev
optimum
regimen
treatment
nhap
includ
durat
therapi
nurs
home
defin
exampl
addit
improv
outcom
addit
macrolid
betalactam
cephalosporin
treatment
nhap
concern
role
resist
organ
mrsa
pseudomona
aeruginosa
etiolog
nhap
clinician
practic
nurs
need
awar
risk
factor
colon
resist
organ
tabl
adjust
empir
therapi
accordingli
import
risk
factor
colon
resist
organ
respiratori
colon
mrsa
pseudomona
aeruginosa
recent
antibiot
therapi
discuss
previou
section
studi
durat
treatment
cap
document
day
equival
day
therapi
term
efficaci
howev
studi
exclud
nurs
home
resid
therefor
studi
durat
nhap
nurs
home
set
consid
might
impact
antibiot
resist
level
well
advers
event
c
difficil
infect
final
urgent
need
specif
nhap
diagnosi
treatment
guidelin
give
nurs
home
provid
guidanc
manag
infect
guidelin
take
consider
hospit
transfer
decis
risk
factor
infect
due
resist
organ
nurs
home
capabl
provid
recommend
regimen
especi
parenter
therapi
followup
treatment
issu
consid
inclus
guidelin
cover
report
includ
prevent
strategi
vaccin
deal
penicillin
allergi
